ScinoPharm Taiwan (Taiwan) Insiders
| 1789 Stock | TWD 23.35 0.15 0.64% |
ScinoPharm Taiwan employs about 47 people. The company is managed by 8 executives with a total tenure of roughly 13 years, averaging almost 1.0 years of service per executive, having 5.88 employees per reported executive. Recap of ScinoPharm Taiwan's management performance can provide insight into the venture performance.
| ChihHsien Lo Chairman Chairman of the Board, Chief Strategy Officer |
ScinoPharm |
ScinoPharm Taiwan Management Team Effectiveness
The company has return on total asset (ROA) of 0.0184 % which means that it generated a profit of $0.0184 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0295 %, meaning that it generated $0.0295 on every $100 dollars invested by stockholders. ScinoPharm Taiwan's management efficiency ratios could be used to measure how well ScinoPharm Taiwan manages its routine affairs as well as how well it operates its assets and liabilities.ScinoPharm Taiwan Workforce Comparison
ScinoPharm Taiwan is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 310. ScinoPharm Taiwan retains roughly 47.0 in number of employees claiming about 15% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.1 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.12 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.12. ScinoPharm Taiwan Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. ScinoPharm Taiwan Price Series Summation is a cross summation of ScinoPharm Taiwan price series and its benchmark/peer.
ScinoPharm Taiwan Notable Stakeholders
A ScinoPharm Taiwan stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ScinoPharm Taiwan often face trade-offs trying to please all of them. ScinoPharm Taiwan's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ScinoPharm Taiwan's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| ChihHsien Lo | Chairman of the Board, Chief Strategy Officer | Profile | |
| Shun Lin | Director Devel | Profile | |
| ChihHui Lin | Sr Off | Profile | |
| LiAn Lu | Deputy General Manager-Administrative Management Center | Profile | |
| Jason Chen | Director Admin | Profile | |
| LingHsiao Lien | VicePres Operations | Profile | |
| BS MS | VP Officer | Profile | |
| LiChiao Chemistry | VP Officer | Profile |
About ScinoPharm Taiwan Management Performance
The success or failure of an entity such as ScinoPharm Taiwan often depends on how effective the management is. ScinoPharm Taiwan management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ScinoPharm management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ScinoPharm management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells CGMP active pharmaceutical ingredients to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. ScinoPharm Taiwan, Ltd. was founded in 1997 and is headquartered in Tainan, Taiwan. SCINOPHARM TAIWAN operates under Drug Manufacturers - Specialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange.
Please note, the imprecision that can be found in ScinoPharm Taiwan's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ScinoPharm Taiwan. Check ScinoPharm Taiwan's Beneish M Score to see the likelihood of ScinoPharm Taiwan's management manipulating its earnings.
ScinoPharm Taiwan Workforce Analysis
Traditionally, organizations such as ScinoPharm Taiwan use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ScinoPharm Taiwan within its industry.ScinoPharm Taiwan Manpower Efficiency
Return on ScinoPharm Taiwan Manpower
| Revenue Per Employee | 58.8M | |
| Revenue Per Executive | 345.3M | |
| Net Income Per Employee | 5.2M | |
| Net Income Per Executive | 30.4M | |
| Working Capital Per Employee | 84M | |
| Working Capital Per Executive | 493.8M |
Additional Tools for ScinoPharm Stock Analysis
When running ScinoPharm Taiwan's price analysis, check to measure ScinoPharm Taiwan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ScinoPharm Taiwan is operating at the current time. Most of ScinoPharm Taiwan's value examination focuses on studying past and present price action to predict the probability of ScinoPharm Taiwan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ScinoPharm Taiwan's price. Additionally, you may evaluate how the addition of ScinoPharm Taiwan to your portfolios can decrease your overall portfolio volatility.